Connect with us

News

Marijuana Retail Report

Published

on

Marijuana Retail Report



“DEA registration marks a historic step forward for our medical business”

TALLAHASSEE, FL, April 29, 2026 /PRNewswire/ — Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) (“Trulieve” or the “Company”), the leading and most effective cannabis company in the United States, today announced that it has filed applications with the U.S. Drug Enforcement Administration (DEA) to register certain state-licensed medical marijuana operations under the expedited registration pathway established by the recent transfer of medical marijuana to Schedule III under the Controlled Substances Act.

“Dea registration for our healthcare business marks a historic step forward for Trulieve and the patients we serve,” said Trulieve Chief Executive Officer Kim Rivers. “With more than 200 medical-only dispensaries, Trulieve is uniquely positioned to set the bar for a responsible operator in the US.”

Following the reclassification of medical marijuana to Schedule III, the DEA established an expedited registration process for eligible state-licensed medical marijuana operators. For operators who have applied within 60 days, a license to manufacture, distribute and dispense Schedule III marijuana medical products is deemed approved unless otherwise noted.

About Truliev
Trulieve is an industry-leading vertically integrated cannabis company and multi-state operator in the US with established hubs in the Northeast, Southeast and Southwest, anchored by corner markets in Arizona, Florida, Ohio and Pennsylvania. Driven by the core mission of expanding access to cannabis, Trulieve offers customers innovative, high-quality branded products and an exceptional experience. With large-scale operations in attractive markets and targeted expansion through a hub strategy, Trulieve is poised for accelerated growth. Trulieve is listed on the CSE under the symbol TRUL and trades on the OTCQX under the symbol TCNNF. For more information, please visit Trulieve.com.

Facebook: @Trulieve
Instagram: @Trulieve
X: @Trulieve

Investor and media contacts
Christine Hersey, Chief Corporate Affairs and Strategy Officer
+1 (424) 202-0210
(email protected)

AI

Marijuana Retail Report

Published

on

By

Marijuana Retail Report



The CPIA tool uses artificial intelligence to scan images of cannabis packaging or labeling

California’s Department of Cannabis Control (DCC) has launched a new AI-based tool designed to help cannabis licensees assess whether the product’s packaging and labeling may be appealing to children.

The Cannabis Product Image Analyzer (CPIA) program, announced by the department this week, allows users to upload photos, screenshots or other supported image files of cannabis packaging and labels. The tool then analyzes the image and provides a summary that indicates whether the package is likely to attract children under the standards set forth in California’s regulations.

According to DCC, the agency does not store uploaded images or resulting summaries.

The department said the tool is designed to help licensees conduct their own independent assessments of packaging and labeling compliance. California regulations prohibit hemp products that are attractive to children.

Examples of prohibited images may include images of minors or persons under the age of 21, cartoons, similes of characters or phrases commonly used to advertise to children, imitation of candy packaging, and use of terms such as “candy,” “candy,” or alternative spellings including “kandi” and “candies.”

Regulators encourage licensees to test the new tool and provide feedback through a public survey. DCC said the responses will help guide future improvements and functionality.

The announcement was included in a broader regulatory update from the department that highlights several ongoing rulemaking efforts.

Among the recent changes, the DCC announced that emergency rules have been adopted to allow retail owners who hold both adult (A) and medical (M) use designations to separate those designations and create a matching M retail license in the same licensed premises. Eligible businesses can request a split through the newly available application process.

The Department is also accepting comments from the public on proposed updates to the Track and Trace system until July 20, 2026. The proposed changes would introduce additional safeguards against fraudulent transactions and potential abuse related to “lab purchases,” and would expand data entry requirements by requiring certain tax information from retailers and requiring retailers to provide certificates of analysis to customers upon request. A public hearing on the proposal is scheduled for July 21.

In addition, regulators continue to seek public input on proposed updates to pesticide testing requirements for cannabis products. Comments on this rulemaking proposal are accepted until June 12.

The DCC also announced upcoming public listening sessions as part of efforts to increase engagement between licensees and department management. In-person sessions are scheduled for June 24 in Redway and July 30 in Sacramento, with additional 2026 dates to be announced at a later date.

In another update, the department said grow license holders who requested both adult and medical use designations can now view both designations on their license certificates and license records. The agency reiterated that licensees can do business with other licensees regardless of whether their licenses are A- or M-designated.

The department said it continues to monitor developments in federal cannabis transfers and will provide updated resources as information becomes available.

The regulatory update also included recent consumer advice regarding the voluntary recall of one Teds Budz flower product due to the presence of Aspergillus terreus, issued on 2 June. Additional recall information remains available on the department’s recall portal.

Continue Reading

Federal

Anti-Rescheduling Parties Ask Court To Stay Schedule III Cannabis Order

Published

on

By

Anti-Rescheduling Parties Ask Court To Stay Schedule III Cannabis Order

A national organization that promotes drug-free workplaces and a pharmaceutical company that specializes in cannabinoids filed a petition in federal court on June 9 to try to stop the Trump administration’s immediate devolution of medical cannabis.

The National Drug and Alcohol Administration Association (NDASA) and MMJ International Holdings, whose subsidiary has an active DEA Schedule I analytical laboratory registration, asked the U.S. Court of Appeals for the District of Columbia Circuit on April 22 to stop U.S. Attorney General Todd Blanche from acting. signed an order reclassifying the state license for medical cannabis to Schedule III until the court case to set aside the entire order is decided.

The plaintiffs argue that the court must consider four factors:

  1. A lawsuit between the human rights group NORML and the Drug Enforcement Administration (DEA) nearly 50 years ago;
  2. The transfer order “illegally” bypassed regulatory notice and comment;
  3. Two plaintiffs will “suffer irreparable harm” without a stay; and
  4. The balance of equity and public interest.

To read the rest of this article on Cannabis Business Times, Click here

Post Parties opposing deadline ask court to delay Schedule III cannabis order first appeared on Marijuana Retail Report – News and information for cannabis retailers.

Continue Reading

News

Marijuana Retail Report

Published

on

By

Marijuana Retail Report



Trulieve has completed a corporate restructuring

Trulieve Cannabis Corp. was the first An American cannabis company has received approval to list on a major US stock exchange.

The voting subsidiary of the Tallahassee, Florida-based company is expected to begin trading on the New York Stock Exchange on Wednesday under the ticker TRLV, the company said in a statement on Friday.

“As the first US cannabis company to go public on a major US exchange, we are excited about the opportunity to expand our shareholder base, increase liquidity and increase awareness of the benefits of medical marijuana,” said Trulieve Founder and CEO Kim Rivers.

“The move to the NYSE is an important development for Trulieve and the industry.”

To read the rest of this article on MJ Biz Daily, Click here

Continue Reading
Advertisement

Trending

Copyright © 2021 The Art of MaryJane Media